NTRK3-rearranged fibrosarcoma

NTRK fusions in malignant tumors are therapeutic targets of tyrosine kinase inhibitors. Because they occur only in a small subset of mesenchymal tumors, knowledge regarding the corresponding histology is important to effectively identify patients who could benefit from targeted therapy.

CD34-positive fibrosarcoma of bone and soft tissue could be a good candidate for NTRK testing.

Paywall references

 Novel NTRK3 Fusions in Fibrosarcomas of Adults. Yamazaki F, Nakatani F, Asano N, Wakai S, Sekimizu M, Mitani S, Kubo T, Kawai A, Ichikawa H, Yoshida A. Am J Surg Pathol. 2019 Apr;43(4):523-530. doi : 10.1097/PAS.0000000000001194 PMID: 30520818